• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What are Clinical Trials?
    • Become a Clinical Trial Volunteer
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » EID Parry acquires Valensa International

EID Parry acquires Valensa International

October 12, 2011
CenterWatch Staff

E.I.D.-Parry (India), the bioproducts and nutraceutical division of the Murugappa Group, has announced the acquisition of 100% of the voting shares of U. S. Nutraceuticals (Valensa International). Valensa will continue to operate as a limited liability company based in Eustis, Florida (USA), with Dr. Rudi E. Moerck as its president and CEO.

Parry acquired a 49% stake in Valensa in 2008. The acquisition was part of Parry's expansion in the North American marketplace and a further build-out of its offerings of branded dietary supplement and condition specific formulations/ingredients including Astaxanthin containing formulations. In the past three years, Valensa and Parry have combined their expertise in micro-algal technology, supercritical CO2 extraction, botanical material sourcing, formulation, product development and global marketing to successfully introduce, science-based ingredients and innovative formulations for health and nutrition.

"There is a huge synergy in this acquisition," according to Sajiv Menon, business head (bio & nutraceuticals) of E.I.D.-Parry. "It provides the platform for Parry to move up the value chain by manufacturing value-added formulations from its ingredients apart from cross selling opportunities in the US and in the rest of the world for both Parry and Valensa," he said. "Valensa's business is now evenly balanced with the company developing science-based, condition-specific formulated products that address unmet needs in Joint Health, Aging, Men's and Women's Health as well as advanced Astaxanthin containing formulations for Eye Health," he added. In the area of eye health, Valensa holds a key patent (US Patent 5,527,533) on the use of astaxanthin, which may mitigate the damaging effects of UV and oxidative stress on the eye, a worldwide problem.

    Upcoming Events

    • 05Dec

      Thriving in Clinical Research – Overcoming Common Challenges as a Site: Part 3 – Site Resourcing

    • 14Apr

      MAGI 2024: The Clinical Research Conference

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Jonathan Seltzer

      Thought Leadership: Remote Patient Monitoring Gives New View of Safety in Cardiac Clinical Trials

    • Quality_Compass-360x240.png

      Ask the Experts: Applying Quality by Design to Protocols

    • Obesity Treatment Patient

      Clinical Trials Need Greater Representation of Obese Patients, Experts Say

    • Modernize-360x240.png

      FDA IT Modernization Plan Prioritizes Data-Sharing, AI, Collaboration and More

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing